Merck putting IT center in Prague; GSK expands API plant in U.K.; Biogen donates hemophilia drugs to developing countries;

@FiercePharma: Allergan board dismisses Valeant bid, but is it running out of options? Report | Follow @FiercePharma

@TracyStaton: Tops online this weekend: Pfizer's move on AstraZeneca outrages pols on two continents. More | Follow @TracyStaton

@EricPFierce: Problems just keep mounting up for Novartis in Japan, this time over events reporting. News | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Pfizer prepares to file for approval with positive PhII MenB data. FierceVaccines story | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) will spend up to £28 million ($47.3 million) to expand a active pharmaceutical ingredient plant in Montrose, U.K. Story

> Japan's Daiichi Sankyo has asked a court in India to withdraw a stay on its sale of Ranbaxy Laboratories to Sun Pharmaceutical that was put in place to allow an investigation into insider trading allegations. Story

> Sanofi ($SNY) is voluntarily recalling three batches of transplant drug Thymoglobuline in the Philippines because of out of specification findings for the product. Story

> Merck ($MRK) will invest about $50 million to create and data analysis center in Prague, Czech Republic that is slated to employ 200 by the end of next year. Story

> Biogen Idec ($BIIB) and Swedish partner Orphan Biovitrum will donate to developing countries over the next decade enough hemophilia drugs to treat tens of thousands of patients. Story

> Danone is negotiating the possible sale of its medical-nutrition business to Nestlé after Fresenius dropped out of the process, sources tell Bloomberg. Story

Medical Device News

@FierceMedDev: Report: Cinven shopping French Dx company Sebia. More | Follow @FierceMedDev

@VarunSaxena2: House votes to make R&D tax credit permanent. What will Senate do? Seems to prefer 2 year extension. Story via WSJ (sub. req.) | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: Double-locked virus needs two enzyme 'keys' to release drugs. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Doctors weigh in on Wikipedia as an evolving--yet flawed--medical text: More from The Atlantic | Follow @EmilyWFierce

> FDA clears prescription video game for rehabilitation therapy. Article

> SI-Bone gets Medicare coverage for its spinal fusion implant. Story

> FDA approves innovative, electrode-powered robotic arm for amputees. News

Biotech News

@FierceBiotech: Show me the money: Which drugs made the top 10 list on upfront deals? Special Report | Follow @FierceBiotech

@JohnCFierce: Lilly draws flak after touting PhIII diabetes success for Lantus rival. More | Follow @JohnCFierce

@DamianFierce: Shire pays $260M for Lumena, getting a rare liver disease treatment and a NASH drug. Story | Follow @DamianFierce

@EmilyMFierce: Potential measles exposure in Fairfax, Loudoun counties investigated. More from The Washington Post | Follow @EmilyMFierce

> Pfizer makes a case for R&D in AstraZeneca megamerger, but does anyone believe it? More

> Chase banks $21M round for Alzheimer's drug research. Item

> Tesaro preps for a Merck showdown after seeing positive PhIII results for rolapitant. Story

CRO News

> Icon wraps up its $143.5M deal for Aptiv. Item

> China's Tigermed buys a $50M stake in a U.S. CRO. Article

> AMRI posts flat revenue as transitional year marches on. More

> Royalty Pharma backs risk-friendly researcher Avillion. Story

> Huntingdon buys Harlan Labs in a bet on CRO growth. Report

Biotech IT News

> Faced with FDA barriers, 23andMe mulls overseas expansion. Item

> U.K. tries to revive 'dead duck' patient data sharing plan. Report

> Debiopharm inks deal with Yale to access computer-aided drug discoveries. Story

> Flatiron raises $130M in Google-led round, buys EMR business. More

> DrugDev buys TrialNetworks to 'glue' its clinical trial apps together. Article

And Finally... A new study shows that by using electrical currents, test patients were able to take control of dreams, like putting on clothes rather than showing up at work naked. Story

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.